USIJ One-Pagers: Why MFN Drug Pricing Fails — and Better Alternatives

USIJ has released two new one-pagers on the dangers of MFN drug pricing and better policy alternatives. MFN would cripple biotech startups, slash R&D, and weaken America’s innovation edge. Instead, policymakers should hold allies accountable, enforce IP rights, and strengthen the patent system.